HypertensionNCT06692413
Withings Devices Follow-up Study - Hypertension
An observational study of Hypertension, run by Withings at 1 site in United States.
Trial summary
The primary objective is to evaluate the accuracy to predict uncontrolled hypertension with Withings device data. Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hypertension
- What is being tested?
- Questionnaire
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Nov 2024to 1 Nov 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The population meeting the inclusion criteria will all live in the US, regular and active users of one or several WITHINGS devices, who agreed to receive notifications from Withings Clinical Operations department, and who have previously acquired a WITHINGS device. They will receive a notification through their WITHINGS application, offering them the opportunity to participate in the study. In case of a positive answer, the user will be redirected to the study information sheet.
Who may be able to join
- Male or female who are 21 years of age or older,
- Participant living in the United States,
- Participant with data recorded in WITHINGS database,
- Active WITHINGS device users having at least 2 years of data,
- Subject able to read, understand, and provide written informed consent,
- Subject willing and able to participate in the study procedures as described in the consent form,
- Subject able to communicate effectively with and willing to follow instructions from the study staff.
Who cannot join
- Minors under 21 years old,
- Subject who refused to participate in the study,
- Subject who did not reply to the questionnaire,
- Subject who objected to the processing of his or her data after the start of the study.
Trial locations and contacts
1 site in 1 country.
United States1 site
Yale University Medical School, Department of Neurology
New Haven, Connecticut, 06150
About this study
The primary objective is to evaluate the accuracy to predict uncontrolled hypertension with Withings device data.
- Conditions
- Hypertension
- Being tested
- Questionnaire
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
Users who consent to the study will receive a questionnaire every 3 months
| Study group | Role | What they receive |
|---|---|---|
| Withings device users | Active Withings device users having at least 2 years of device data Receives: Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prediction of uncontrolled hypertension
Correlation between uncontrolled hypertension, Withings data, and survey answers
Measured: 2 years
Secondary outcomes (2)
Correlation between Framingham risk score and EQ-5D-5L answers and Withings data
Correlation between Framingham risk score and EQ-5D-5L answers and Withings data
Measured: 2 years
Number of Questionnaires answers per participant
Number of Questionnaires answers per participant
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2024
- Study start1 Nov 2024
- Primary completion1 Nov 2024
- Study completion1 Nov 2024
Why it stopped: The PI couldn't participate to the study finally
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Withings
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- de Havenon, MD, Principal investigator, Yale University School of Medicine, Dept of Neurology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06692413
- Sponsor's protocol ID
- WIQUEST-HTA
- Status last verified
- Feb 2026
- First submitted
- 12 Nov 2024
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Withings Devices Follow-up Study - Hypertension
- ClinicalTrials.gov ID
- NCT06692413
- Acronym / sponsor ID
- WIQUEST-HTA
- Conditions
- Hypertension
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: The PI couldn't participate to the study finally
- Enrolment
- 0 participants (actual)
- Lead sponsor
- WithingsIndustry (pharma, biotech, devices)
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Nov 2024 (actual)
- Study completion
- 1 Nov 2024 (actual)
- First posted
- 18 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective is to evaluate the accuracy to predict uncontrolled hypertension with Withings device data.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Withings device users | – | Other: QuestionnaireActive Withings device users having at least 2 years of device data |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The population meeting the inclusion criteria will all live in the US, regular and active users of one or several WITHINGS devices, who agreed to receive notifications from Withings Clinical Operations department, and who have previously acquired a WITHINGS device. They will receive a notification through their WITHINGS application, offering them the opportunity to participate in the study. In case of a positive answer, the user will be redirected to the study information sheet.
Key inclusion criteria (7 listed)
- Male or female who are 21 years of age or older,
- Participant living in the United States,
- Participant with data recorded in WITHINGS database,
- Active WITHINGS device users having at least 2 years of data,
- Subject able to read, understand, and provide written informed consent,
Key exclusion criteria (4 listed)
- Minors under 21 years old,
- Subject who refused to participate in the study,
- Subject who did not reply to the questionnaire,
- Subject who objected to the processing of his or her data after the start of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireUsers who consent to the study will receive a questionnaire every 3 months | Other | Withings device users |
Primary outcome
Prediction of uncontrolled hypertension
Time frame: 2 years
Correlation between uncontrolled hypertension, Withings data, and survey answers
2 secondary outcomes
Correlation between Framingham risk score and EQ-5D-5L answers and Withings data
Time frame: 2 years
Number of Questionnaires answers per participant
Time frame: 2 years
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
Related trials for Hypertension
Not yet recruitingPhase 4
An Investigator-initiated, Prospective, Open-label, Multicenter Randomized Controlled Trial, Comparing the Efficacy of Sacubitril/Valsartan and Standard Treatment on Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients Without Hypertensive
Atrial Fibrillation (Persistent), Catheter Ablation
Recruiting
Effects of Balance Training in Individuals With Glaucoma
Glaucoma
RecruitingPhase 4
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Hypertension, Hypercortisolemia
Not yet recruitingObservational study
Development and Validation of a TIPS Prognostic Model
Portal Hypertension Related to Cirrhosis, Ascites
RecruitingPhase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Pulmonary Arterial Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
de Havenon, MD principal investigator
Yale University School of Medicine, Dept of Neurology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by Withings at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prediction of uncontrolled hypertension (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.